Moxifloxacină Rompharm (Moxifloxacin)

Moxifloxacin works by inhibiting two essential bacterial enzymes: DNA gyrase (topoisomerase II) and topoisomerase IV. These enzymes are required for DNA replication, transcription, and supercoiling. By blocking their activity, moxifloxacin prevents bacterial cells from dividing and ultimately leads to bacterial cell death, providing a broad‑spectrum antibacterial effect.

The dose of Moxifloxacină Rompharm is determined by the prescribing healthcare professional based on the type and severity of the infection, patient weight, renal and hepatic function, and any relevant comorbidities. Dosage regimens are individualized and should follow the latest clinical guidelines and the prescriber’s judgment.

Moxifloxacin is classified as a pregnancy category that should be used only when the potential benefits justify the potential risks to the fetus. Limited data exist for breastfeeding, and the drug may be excreted in breast milk. Healthcare providers should assess the risk‑benefit ratio before prescribing to pregnant or lactating patients.

To order Moxifloxacină Rompharm, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will request trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed), and assist with import documentation.

Moxifloxacin offers a broader spectrum against both Gram‑positive and atypical pathogens compared with many older fluoroquinolones, and it has a lower propensity for inducing resistance in certain bacteria. It also provides enhanced tissue penetration, especially in respiratory tissues. However, safety considerations such as QT prolongation and tendon toxicity remain similar across the class, requiring careful patient selection.

Moxifloxacină Rompharm should be stored refrigerated at 2‑8 °C (36‑46 °F). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If the product reaches room temperature for a short period during administration, it may be used, but it should be returned to the refrigerator promptly.

Moxifloxacină Rompharm is administered intravenously by a qualified healthcare professional. The solution is typically diluted in an appropriate compatible IV fluid and infused over a specified period, usually 30‑60 minutes, depending on the clinical protocol. Administration should follow aseptic technique and institutional infusion guidelines.

The most serious risks include tendon rupture (especially the Achilles tendon), QT interval prolongation leading to potentially fatal cardiac arrhythmias, severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome, and Clostridioides difficile‑associated colitis. Patients should be monitored closely for these events, and therapy should be discontinued immediately if they occur.

Moxifloxacin should be avoided in patients with a known hypersensitivity to fluoroquinolones, a history of tendon disorders related to fluoroquinolone use, or those with significant QT prolongation or uncontrolled cardiac arrhythmias. Caution is also advised for patients with severe renal or hepatic impairment, and it is generally contraindicated in pregnant or breastfeeding women unless the benefits outweigh the risks.